Literature DB >> 15564269

Completion lymphadenectomy may not increase in-transit disease in malignant melanoma.

Robin Russell-Jones, Ciaran Healy, Ann-Marie Powell, Katharine Acland, Michael O'Doherty, Eduardo Calonje.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15564269      PMCID： PMC534491          DOI： 10.1136/bmj.329.7477.1288-c

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  The argument against sentinel node biopsy for malignant melanoma.

Authors:  J M Thomas; E J Patocskai
Journal:  BMJ       Date:  2000-07-01

2.  Sentinel lymph node biopsy: not yet standard of care for melanoma.

Authors:  J Meirion Thomas; Matthew A Clark
Journal:  BMJ       Date:  2004-07-17

3.  Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.

Authors:  F Meier; S Will; U Ellwanger; B Schlagenhauff; B Schittek; G Rassner; C Garbe
Journal:  Br J Dermatol       Date:  2002-07       Impact factor: 9.302

4.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

Authors:  Keith Wheatley; Natalie Ives; Barry Hancock; Martin Gore; Alexander Eggermont; Stefan Suciu
Journal:  Cancer Treat Rev       Date:  2003-08       Impact factor: 12.111
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.